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The aim of this randomized, open, parallel group study was to compare the clinical efficacy of formoterol dry 
powder capsule 12pg b.i.d. and salmeterol dry powder 5Opg b.i.d. in the treatment of patients with reversible 
obstructive airways disease. The 6-month treatment was preceded by a 2 week run-in period. Morning pre-dose peak 
expiratory flow (PEF) during the last 7 days of treatment was the primary variable. Throughout the study, patients 
recorded morning and evening pre-dose PEF, use of rescue medication, respiratory symptoms and adverse events. 
Clinic visits were scheduled at monthly intervals. Of the 482 patients randomized (equal numbers in the two 
treatment groups), 428 completed the study. Four hundred and twenty-five patients were included in the efficacy 
analysis for the primary variable. 
For mean morning pre-dose PEF during the last 7 days of treatment, the 95% confidence interval (CI) for the 
treatment contrast formoterol minus salmeterol was included entirely in the pre-defined range of equivalence (CI 
limits= - 8.69, +9.84 1 min - ‘). This was also the case for the morning PEF during the last week before each clinic 
visit. For mean evening pre-dose PEF, the estimated treatment contrasts showed a trend towards superiority of 
formoterol over salmeterol, which became statistically significant at 2, 3 and 4 months (PcO.05; estimated contrasts 
7.27, 10.45 and 10.51 1 min- ‘, respectively). No treatment group differences were found in use of rescue medication 
and respiratory symptom scores. The incidence of adverse events was similar in the two groups. 
These findings demonstrate that formoterol 12pg b.i.d. and salmeterol 5Opg b.i.d., both formulated as dry 
powders, have similar long-term efficacy and safety profiles in patients with reversible obstructive airways disease. 
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Introduction 
&agonists continue to be a cornerstone in the treatment of 
bronchial asthma. These agents are the most effective drugs 
available for the relief of acute asthma symptoms (1). Until 
recently, their therapeutic usefulness was limited by a 
relatively short duration of action, necessitating frequent 
administration and resulting in insufficient protection 
against, for example, nocturnal asthma. 
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Formoterol and salmeterol are the first drugs of a new 
generation of long-acting ,&-agonists (2). Both compounds, 
when administered as an aerosol by a metered dose inhaler 
(MDI) or when inhaled as a powder, induce symptomatic 
relief of wheezing and breathlessness, with a duration of 
action of at least 12 h. Whereas short-acting /&-agonists 
have been recommended for use only as a relief medication, 
inhaled long-acting &adrenoceptor agonists are usually 
prescribed for regular use in patients with asthma who are 
still symptomatic while receiving inhaled cortico- 
steroid therapy. In these patients, clinical studies have 
indicated that chronic treatment with long-acting 
&-agonists improves symptom score, decreases nocturnal 
asthma, improves lung function, and decreases the use of 
short-acting inhaled &-agonists (336). 
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or 5Opg salmeterol dry powder (SEREVENT@ 
DISKHALERB). A computer-generated randomization 
scheme was used to provide balanced blocks of patient 
numbers for the two treatment groups within each country. 
A one-to-one treatment allocation and a block size of eight 
were used. No formal checks of patient compliance with 
dosing regimens were made. 
In vitro comparative studies have shown evidence of 
differences between formoterol and salmeterol with respect 
to onset and duration of action and dose-dependency of 
effects (7). At the present time, four comparative single- 
dose studies have been published as full papers, two in 
patients with bronchial asthma (8,9) and two in patients 
with chronic obstructive pulmonary disease (COPD) 
(10,ll). A direct comparison of efficacy and safety during 
long-term treatment is still lacking. 
We conducted a multinational, randomized, open 
study using a population of patients with reversible 
obstructive airways disease who could benefit from the use 
of regular inhaled long-acting &agonists. We compared 
the clinical efficacy and safety of &month treatment with 
either formoterol dry powder capsule 12pg twice daily or 
salmeterol dry powder 50 pg twice daily. 
Methods 
STUDY SUBJECTS 
Out-patients suffering from moderate-to-severe reversible 
obstructive airways disease were entered into the study. 
Patients were of both sexes, aged 18 years or older. Patients 
were required to have had a documented diagnosis of 
reversible obstructive airways disease for 1 yr or more and 
to be using regular inhaled corticosteroids at a constant 
dose of at least 400 pug day ~ ’ (or 200 ,ug day- i fluticasone) 
for at least 1 month before inclusion. Patients were 
excluded from participation if they had evidence of other 
clinically relevant diseases. Pregnant or lactating women 
were also excluded. Patients on P-blocker therapy or with 
hypersensitivity to sympathomimetic amines or inhaled 
lactose were excluded, as were those who were considered 
unable to comply with the study protocol. Inhaled cortico- 
steroids were continued at a constant dose throughout the 
study. 
Although the vast majority of patients selected according 
to the above inclusion criteria would have been patients 
with bronchial asthma, no attempt was made to exclude (or 
differentiate) patients with COPD, as long as bronchial 
reversibility had been demonstrated. This was done in order 
to obtain a sample which was representative of the patient 
population receiving inhaled long-acting &agonists in 
daily clinical practice. 
STUDY DESIGN 
The trial was a randomized, parallel group, open study. 
A total of 41 centres, in France, Italy, Spain, Sweden, 
Switzerland and the U.K., participated. Following a 2 week 
run-in period, when patients recorded baseline symptoms, 
use of rescue medication (salbutamol MD1 100 pg puff - * 
or salbutamol dry powder 200 pug dose - ‘) and twice daily 
peak expiratory flow (PEF) measurements, patients who, 
according to the investigator(s), could benefit from the 
regular use of a long-acting &-agonist were allocated to 
6 months of twice daily treatment with 12pg formoterol 
dry powder (FORADIL@) administered via the Aerolizer@ 
METHODS 
At home, using a mini-Wright peak flow meter, patients 
measured their PEF at about 12 h intervals, in the morning 
(6 to 9 a.m.) and evening (6 to 9 p.m.). PEF measurements 
(highest of three consecutive measurements) had to be 
performed before intake of trial medication and the values 
entered in diary cards. Patients were asked not to take 
rescue medication 6 h prior to the PEF measurements. If 
rescue medication was used, this was noted in the diary 
card. In addition, respiratory symptoms and adverse events 
were recorded. Day- and night-time respiratory symptoms 
were scored on a five grade scale (O=best to 4=worst). 
Patients visited the clinic before and after the run-in period 
and every 4th week of the treatment period. At each clinic 
visit, medication were reviewed and diary cards were col- 
lected. The study was conducted in accordance with the 
Declaration of Helsinki and the principles of Good Clinical 
Practice and was approved by the Ethics Committees of 
the participating centres. Signed informed consent was 
obtained from all patients before recruitment. 
ANALYSIS 
The primary variable was the mean morning pre-dose PEF 
during the last 7 days of treatment and the minimum 
sample size required for the study was determined in 
relation to its statistical power to detect treatment differ- 
ences in mean PEF. Assuming an upper limit for the true 
standard deviation of mean morning PEF of 48 1 min - ’ 
and the use of two-sided significance test at the 5% level, 
then a total of 180 evaluable patients (90 per treatment) 
would have given the study a power of 80% to detect mean 
differences in PEF of approximately 20 1 mini i. The 
sample size was then doubled in order to allow meaningful 
comparisons in a concomitant assessment of quality of 
life (manuscript in preparation). Secondary end-points 
included mean morning and evening pre-dose PEF during 
the last week before each clinic visit, overall mean morning 
and evening pre-dose PEF for the entire treatment period, 
day- and night-time use of rescue medication, and day- and 
night-time symptom scores. 
The primary efficacy variable and the corresponding 
variable derived from the evening pre-dose PEF were 
analysed for the population of patient completing the entire 
treatment period. All other efficacy variables were analysed 
for those patients who received at least one dose of trial 
medication and who had at least one measurement during 
the treatment period. All randomized patients who received 
at least one dose of trial medication were included in the 
safety analysis. Tests for baseline homogeneity of treatment 
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TABLE 1. Summary of demographic and baseline data 
Formoterol Salmeterol 
(n=241) (n=241) 
Total 
(n=482) 
Age (years) 
Mean (range) 
Sex (12 %) 
Males 
Females 
Smoking history (n %) 
Current smokers 
Ex-smokers 
Never smoked 
Duration of obstructive airways disease (years) 
Mean (range) 
Morning PEF (1 min - ‘) 
Mean (range) 
Evening PEF (1 min ~ ‘) 
Mean (range) 
Day-time intake of rescue medication (number of puffs)* 
Mean (range) 
Night-time intake of rescue medication (number of puffs)* 
Mean (range) 
Day-time symptom score* 
Mean (range) 
Night-time symptom score* 
Mean (range) 
48 (18-78) 
108 (45) 
133 (55) 
36 (14.9) 
70 (29.0) 
135 (56.0) 
15.8 (1.1-54.0) 
377 (110-670) 
388 (97-744) 
2.1 (O-17.6) 
1.2 (O-10.9) 
0.9 (040) 
0.6 (04.0) 
47 (18-77) 
113 (47) 
128 (53) 
38 (15.8) 
77 (32.0) 
126 (52.3) 
16.3 (0.7-64.0) 
371 (89-749) 
384 (1499800) 
1.9 (O-15.1) 
1.1 (O-10.9) 
0.8 (O-3.7) 
0.5 (O-3.0) 
48 (18-78) 
221 (46) 
261 (54) 
74 (15.4) 
147 (30.5) 
261 (54.1) 
16.0 (0.7-63.0) 
374 (89-749) 
386 (97-800) 
2.0 (O-17.6) 
1.2 (O-10.9) 
0.9 (040) 
0.6 (O-4.0) 
*Mean of the last seven days of the 2-week run-in phase. 
groups were not performed. Instead, treatment group 
differences at baseline were adjusted for by including 
appropriate variables in the statistical model. 
The primary efficacy variable was analysed by means of 
an analysis of covariance (ANCOVA) with fixed effects for 
treatment, country, centre within country and sex, and with 
the baseline value (last 7 days before the randomiz- 
ation visit) as a covariate. The treatment comparison 
was assessed by constructing, based on the ANCOVA, a 
two-sided 95% confidence interval (CI) for the contrast 
formoterol minus salmeterol. Equivalence was meant one- 
sided with a limit of 20 1 min - I. Treatment equivalence 
would therefore have been demonstrated if the CI for the 
contrast formoterol minus salmeterol laid entirely above 
the -2Olmin’ value, i.e. if the mean morning pre-dose 
PEF during the last 7 days of treatment in the formoterol 
group was at most 20 1 min ~ ’ lower than in the salm- 
eterol group. To account for the possible effect of the 
intake of rescue medication, a secondary exploratory 
analysis was performed, where all measurements for 
which an intake of rescue medication within the previous 
6 h had been recorded were excluded. All other efficacy 
variables related to PEF were analysed in the same way as 
the primary variable. Differences in use of rescue medica- 
tion were analysed with the van Elteren test (12) stratified 
for centre and, additionally, with the same ANCOVA 
model as the primary efficacy variable. Mean symptom 
scores were analysed with the van Elteren test stratified 
for centre. 
Results 
PATIENTS 
This multicentre study enrolled 529 patients. Forty-seven 
patients were not randomized; the most frequent reasons 
were failure to meet the inclusion criteria (17 patients), 
non-compliance with study procedures (eight patients) and 
withdrawal of consent (eight patients). Thus, 482 patients 
were randomized to treatment. 
Two hundred and forty-one patients were randomized to 
receive formoterol 12pg b.i.d. and the same number to 
receive salmeterol 50,~g b.i.d. The groups were well- 
matched for demographical details. Patients’ baseline char- 
acteristics are described in Table 1. Approximately 80% of 
patients used salbutamol MD1 as rescue medication. There 
were no significant differences in terms of use of concomi- 
tant medications, including inhaled corticosteroids, 
between the two treatment groups. 
Twenty-four patients from the formoterol group and 30 
patients from the salmeterol group were withdrawn after 
randomization. Of these, 26 patients were withdrawn 
because of adverse events, five because of unsatisfactory 
FORMOTEROL AND SALMETEROL IN LONG-TERMUSE 839 
430 
(a) 
420 
0-r I I I I I I 
Baseline 1 2 3 4 5 6 
430 
(b) 
420 
370 
$ 
0 I I I 
Baseline 1 2 3 4 5 6 
Time (months) 
FIG. 1. Mean morning (a) and evening (b) pre-dose peak 
expiratory flow (PEF) over the run-in and treatment 
periods (mean of last 7 days before each clinic visit). 
(+-), formoterol; (a-), salmeterol. 
therapeutic effect, one for not meeting the protocol criteria, 
eight for non-compliance, six for withdrawal of consent, 
two because of administrative problems and six were lost to 
follow-up. There were no differences between treatment 
groups in the pattern of reasons for premature discontinu- 
ation of trial medication. 
The efficacy primary end-point could be analysed for 425 
of the 428 patients completing the study, since for three 
patients no PEF measurements were available in the diary 
for the last 7 days of treatment. All 482 patients who used 
the study medication were included in the safety analysis. 
PEF MEASUREMENTS 
The mean values for the run-in and treatment periods in 
morning and evening pre-dose PEF are presented in Fig. 1. 
For the primary efficacy end-point, mean morning pre- 
dose PEF during the last 7 days of treatment, the 95% CI 
for the treatment contrast formoterol minus salmeterol was 
- 8.69, +9.84 1 min - i and was included entirely in the 
pre-defined range of equivalence (Fig. 2). This was also the 
case for mean morning pre-dose PEF during the last week 
before each clinic visit. The analysis excluding measurement 
after intake of rescue medication essentially confirmed the 
primary analysis. 
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FIG. 2. Treatment contrasts (formoterol minus 
salmeterol) including 95% CI of mean morning (a) and 
evening (b) pre-dose peak expiratory flow (PEF) over 
time (mean of last 7 days before each clinic visit). 
For mean evening pre-dose PEF, the estimated treatment 
contrasts showed a trend towards superiority of formoterol 
over salmeterol, which became statistically significant at 2, 
3 and 4 months (P~0.05, estimated contrasts 7.27, 10.45 
and 10.51 1 min- ‘, respectively) (Fig. 2). Also in this case, 
the analysis excluding measurements after an intake of 
rescue medication led to similar results. 
USE OF RESCUE MEDICATION 
At all visits, mean intake of rescue medication was found to 
be less than half of the baseline value for both treatment 
groups (Fig. 3). This was seen both at day- and night-time. 
No statistically significant difference between the two treat- 
ment groups was seen at any visit. 
RESPIRATORY SYMPTOM SCORE 
Mean symptom scores improved in both treatment groups 
in a similar way (Fig. 4). The percentage of days with a 
symptom score=0 increased in both treatment groups by 
about the same extent. The symptom score improvements 
were similar for both day- and night-time periods. There 
was no statistically significant treatment group difference at 
any examination. 
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31 SAFETY 
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FIG. 3. Mean number of puffs of rescue medication 
inhaled during day- (a) and night-time (b) over time 
(mean of the last 7 days before each clinic visit). (u), 
formoterol; (m), salmeterol. 
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FIG. 4. Mean respiratory symptom score at day- (a) and 
night-time (b) over time (mean of the last 7 days before 
each clinic visit). (o), formoterol; (I), salmeterol. 
Both treatments were safe and well tolerated. Although 
adverse events were reported by 190 (79%) patients in the 
formoterol group and 193 (80%) patients in the salmeterol 
group, this is not unexpected in a trial of 6 month duration. 
No treatment group differences were seen. Most frequent 
adverse events included viral infection, asthma exacer- 
bation, headache, rhinitis and chest infection. Exacerbation 
of asthma was reported as an adverse event by 41 patients 
(17%) in the formoterol group and 54 patients (22%) in the 
salmeterol group. 
When considering only adverse events which were 
assessed by the investigator as possibly/probably trial drug- 
related, events were reported in 32 (13%) patients who 
received formoterol and 21 (9%) patients who received 
salmeterol. The most frequent possibly/probably trial drug- 
related adverse event was headache (seven patients in the 
formoterol group and 11 in the salmeterol group). Other 
possibly/probably trial drug-related adverse events included 
tremor (seven patients, five with formoterol and two with 
salmeterol), asthma exacerbation (eight patients, four in 
each group) and palpitations (four patients, all of them in 
the formoterol group). 
Discussion 
To our knowledge, this is the first study in which the 
long-term effects of formoterol and salmeterol on lung 
function and symptom control have been directly com- 
pared. In this mixed population of patients with reversible 
airways obstruction, which is likely to be representative of 
patients receiving inhaled long-acting &agonists in clinical 
practice, formoterol dry powder capsule 12pg b.i.d. and 
salmeterol dry powder 50 pug b.i.d. were equally effective in 
terms of PEF values and symptom control. 
This was an open-label trial. The use of a double-dummy 
design would have been necessary to achieve double- 
binding. This would have added to the already fairly 
onerous long-term trial schedule. The use of an open design 
is unlikely, however, to have introduced significant bias. 
The patient information document merely stated that the 
two treatments would be compared, without indicating that 
formoterol was a newer medication. In addition, the main 
efficacy variable was derived from objective measurements 
(PEF). 
In vitro studies have shown that formoterol is a more 
potent &adrenoceptor agonist and has a faster onset of 
action than salmeterol, but that the duration of action is 
longer for salmeterol (7). In addition, the in vitro duration 
of action of formoterol, but not of salmeterol, was found to 
be dose-dependent. 
There have been a number of studies comparing 
the effects of single doses of formoterol and salmeterol 
on airway tone. Rabe and co-workers found that 12,ug 
formoterol and 50 pug of salmeterol were equally effective in 
mild asthmatics in protecting against methacholine-induced 
bronchoconstriction for up to 24 h (8). In a study published 
as an abstract by Zellweger and colleagues, 50 pg salmeterol 
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and 24 pg formoterol produced comparable protection 
against methacholine-induced bronchoconstriction during 
at least 16 h (13). Cazzola and co-workers compared the 
effects of 5Opg salmeterol and 24,ug formoterol in 16 
patients with COPD and concluded that both compounds 
were equivalent in terms of maximum bronchodilation and 
duration of action (10). However, in a second study in 12 
patients with COPD, the same authors reported that 5Opg 
salmeterol had a longer duration of action than 12 or 24 pug 
formoterol (ll), in contrast with their own previous find- 
ings. In a preliminary report on six patients with mild 
asthma, Dal Negro’s group has shown that formoterol 
24 ,ug and salmeterol 5Opg, but not formoterol 12pg, 
protected against methacholine-induced bronchoconstric- 
tion for 12 h (14). In contrast, another preliminary report 
has claimed a longer duration of action of 12pg formoterol 
over 50 ,ug salmeterol in nine patients with partially revers- 
ible COPD (15). Recently, van Noord and co-workers have 
compared single doses of formoterol 24,ug, salmeterol 
50 pug and salbutamol 2OOpg and have concluded that, in 
patients with moderately severe asthma, formoterol and 
salmeterol had an equal bronchodilatory capacity, which 
lasted for at least 12 h and that formoterol had a more 
rapid onset of action than salmeterol, equal to that of 
salbutamol (9). However, the clinical significance of the 
study was hampered by the lack of a formoterol 12 pug arm, 
which is the dose of formoterol recommended in the vast 
majority of patients (16). 
During recent years, several guidelines for asthma and 
COPD treatments have been published. Although the role 
of inhaled long-acting &agonists in the management of 
COPD patients remains to be determined (17) asthma 
guidelines agreed that regular bronchodilator drug use 
should be recommended when asthma symptoms and func- 
tional abnormalities are not completely controlled by regu- 
lar use of inhaled corticosteroids (1). One of the issues to 
address is, therefore, the choice between formoterol and 
salmeterol. 
Our study in a large number of patients with reversible 
airways obstruction demonstrates that, during 6 months of 
treatment, formoterol 12pg b.i.d. and salmeterol 5Opg 
b.i.d. have similar clinical efficacy in terms of morning PEF, 
use of rescue medication and symptom score. This sug- 
gests that the in vitro longer duration of action of salmeterol 
does not have clinical relevance. A surprizing result of 
the present study was the trend towards superiority 
of formoterol over salmeterol in terms of evening PEF, 
which became statistically significant at 2, 3 and 4 months. 
Further studies, including assessment of patients’ com- 
pliance, are needed to investigate the reasons for this 
finding. 
In conclusion, our study demonstrates that formoterol 
dry powder capsule 12pg b.i.d. and salmeterol powder 
50 fig b.i.d. are equally effective in controlling lung function 
and symptoms in patients with reversible airways disease 
who take regular inhaled steroids. In addition, they have 
similar safety profiles. Features other than the ilz vitro 
longer duration of action of salmeterol should, therefore, 
guide the therapeutic choice between these two drugs, 
including the impact of speed of onset of action (16) and 
type of inhalation device (18) on patients’ compliance with 
treatment. 
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